NCT06049095View on ClinicalTrials.gov

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Healthy
Interventions
DRUG

LTG-001

Oral doses

DRUG

Placebo

Oral doses

Trial Locations (1)

Unknown

Clinical Research Unit, Christchurch

Sponsors
All Listed Sponsors
lead

Latigo Biotherapeutics

INDUSTRY